276 related articles for article (PubMed ID: 35204371)
1. Role of Combined
Kaewput C; Vinjamuri S
Diagnostics (Basel); 2022 Jan; 12(2):. PubMed ID: 35204371
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
3. Role of Combined [
Carideo L; Prosperi D; Panzuto F; Magi L; Pratesi MS; Rinzivillo M; Annibale B; Signore A
J Clin Med; 2019 Jul; 8(7):. PubMed ID: 31337043
[TBL] [Abstract][Full Text] [Related]
4. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
5. The predictive impact of dual somatostatin receptor/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience.
Mohamed A; Asa SL; Lee Z; Tirumani SH; Li Q; Avril N; Bajor D; Mahipal A; Chakrabarti S; Selfridge JE; Kardan A
J Gastrointest Oncol; 2023 Apr; 14(2):1087-1094. PubMed ID: 37201086
[TBL] [Abstract][Full Text] [Related]
6. Detection of Bone Metastases by
Tian R; Xie Q; Yu F; Du C; Yao X; Zang S; Zhang C; Zhang P; Shao G; Yang Z; Wang F; Yu J
Contrast Media Mol Imaging; 2022; 2022():1750132. PubMed ID: 36447752
[TBL] [Abstract][Full Text] [Related]
7. Combined Quantification of
Lee H; Nakamoto R; Moore SE; Pantel AR; Eads JR; Aparici CM; Pryma DA
Acad Radiol; 2022 Sep; 29(9):1308-1316. PubMed ID: 34836776
[TBL] [Abstract][Full Text] [Related]
8. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
[TBL] [Abstract][Full Text] [Related]
9. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
[TBL] [Abstract][Full Text] [Related]
10. Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: A review.
Evangelista L; Ravelli I; Bignotto A; Cecchin D; Zucchetta P
Clin Imaging; 2020 Nov; 67():113-116. PubMed ID: 32559681
[TBL] [Abstract][Full Text] [Related]
11. PET/CT and PET/MRI in neuroendocrine neoplasms.
Rajamohan N; Khasawneh H; Singh A; Suman G; Johnson GB; Majumder S; Halfdanarson TR; Goenka AH
Abdom Radiol (NY); 2022 Dec; 47(12):4058-4072. PubMed ID: 35426497
[TBL] [Abstract][Full Text] [Related]
12. Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.
Calabrò D; Argalia G; Ambrosini V
Diagnostics (Basel); 2020 Dec; 10(12):. PubMed ID: 33297381
[TBL] [Abstract][Full Text] [Related]
13. Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors.
Ambrosini V; Zanoni L; Filice A; Lamberti G; Argalia G; Fortunati E; Campana D; Versari A; Fanti S
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205805
[TBL] [Abstract][Full Text] [Related]
14. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
15. Role of positron emission tomography in thyroid and neuroendocrine tumors.
Treglia G; Kroiss AS; Piccardo A; Lococo F; Santhanam P; Imperiale A
Minerva Endocrinol; 2018 Sep; 43(3):341-355. PubMed ID: 28949122
[TBL] [Abstract][Full Text] [Related]
16. Comparison of gallium-68 somatostatin receptor and
Liu X; Li N; Jiang T; Xu H; Ran Q; Shu Z; Wu J; Li Y; Zhou S; Zhang B
Hell J Nucl Med; 2020; 23(2):188-200. PubMed ID: 32716410
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Survival and Value of
Rodrigues M; Winkler KK; Svirydenka H; Nilica B; Uprimny C; Virgolini I
Life (Basel); 2021 Mar; 11(3):. PubMed ID: 33806393
[TBL] [Abstract][Full Text] [Related]
18. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.
Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C
Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632
[TBL] [Abstract][Full Text] [Related]
19. Glucose Metabolism Modification Induced by Radioligand Therapy with [
Urso L; Panareo S; Castello A; Ambrosio MR; Zatelli MC; Caracciolo M; Tonini E; Valpiani G; Boschi A; Uccelli L; Cittanti C; Bartolomei M
Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297443
[TBL] [Abstract][Full Text] [Related]
20. The Correlation Between [
Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
